拉米夫定联合水飞蓟宾-卵磷脂复合物治疗慢性乙型肝炎疗效观察

目的观察拉米夫定联合水飞蓟宾-卵磷脂复合物(SLC)治疗慢性乙型病毒性肝炎的临床疗效。方法88例慢性乙型病毒性肝炎患者分为2组,观察组44例,口服拉米夫定100 mg,每日1次,同时口服水林佳(水飞蓟宾-卵磷脂复合物)105 mg(3粒),每日3次,连服48周;对照组44例单服拉米夫定48周。于治疗第12周、第24周、第48周及停药后24周分别检测2组患者血清乙型病毒性肝炎病毒标志物(HbeAg)、乙型肝炎病毒(HBV)DNA定量、丙氨酸转氨酶(ALT)等,并观察不良反应。结果观察组治疗第48周及停药后24周ALT的复常率和HBV DNA转阴率均明显高于对照组(P<0.05);观察组治疗第12周、第24周、第48周及停药后24周的HBeAg转阴率均明显高于对照组(P<0.05);2组不良反应发生率比较无显著差异(P>0.05)。结论拉米夫定联合水飞蓟宾-卵磷脂复合物治疗慢性乙型肝炎能更有效地提高ALT复常率和HBeAg阴转率,降低血清HBV DNA水平,且不良反应轻。

Curative effect of lamivudine and silybin-leeithin compound on 88 patients with chronic hepatitis B

Objective To observe the clinical curative effect of lamivudine and silybin-lecithin compound(SLC) for treatment of 88 patients with chronic hepatitis B.Methods Eighty-eight patients with chronic hepatitis B were randomly divided into two groups.Forty-four cases were treated with lamivudine 100 mg orally once a day,and SLC 105 mg orally three times a day for 48 weeks in observation group;Forty-four cases were treated with lamivudine only for 48 weeks in control group.the serum markers of hepatitis B e antigen,HBV DNA quantification and alanine aminotransferase(ALT) were detected on the 12th,24th,and 48thweek during treatment as well as 24 weeks after treatment,and the adverse effect was observed in two groups.Results The recovery rate of ALTand the rate of HBVDNAin the observation group within 48 weeks of treatment and 24 weeks after discontinuation of medicine was significantly higher than these in the control group(P<0.05).On the 12th,24th and 48th week during treatment and 24 weeks after discontinuation of medicine,the negative rate of HBeAg in observation group was obviously higher than that in control group(P<0.05).There was no obviously difference in the rate of adverse response between two groups(P>0.05).Conclusion Using Lamivudine combined with SLC to treat the patients with chronic hepatitis B could effectively increase the recovery rate of ALTand the negative rate of HBeAg,reduce the level of blood serum HBVDNA,and the adverse effect was low.